Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 4 of 4

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Ferroptosis, Extracellular Vesicles and Circulating Tumor DNA as Potential Biomarkers for Uveal Melanoma Prognostication

Valentina Tonelotto; Eve O'Reilly; Marcel Costa-Garcia; Kieran Wynne; Valerie O'Neill; Patrick Murtagh; Ellie Swords; Laura Ivers; Flordeliza Calacsan; Luisa Weiss; Patricia Maguire; Joseph M. Piulats; John Crown; Paula Calvert; Noel Horgan; Breandan N Kennedy

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1472.

ARVO Annual Meeting Abstract June 2022

CysLT 1 antagonist, 1,4-dihydroxy quininib, alters the secretion of inflammatory mediators from primary uveal melanoma explants and reduces ATP5B expression in a metastatic xenograft model.

Kayleigh Slater; Rosa Bosch; Chowdhury Arif Jahangir; Arman Rahman; Fiona O'Connell; Josep M. Piulats; Sarah E Coupland; Valerie O'Neill; Noel Horgan; Jacintha O'Sullivan; William Gallagher; Alberto Villanueva; Breandan N Kennedy

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2352 – A0021.

ARVO Annual Meeting Abstract April 2009

A Pilot Study Comparing the Efficacy of Intravitreal Bevacizumab Versus Intravitreal Triamcinolone in the Treatment of Macular Edema Following Plaque Radiotherapy for Uveal Melanoma

N. Horgan; C. L. Shields; A. Mashayekhi; J. A. Shields

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):3383.

ARVO Annual Meeting Abstract May 2008

Macular Edema Following Plaque Radiotherapy of Uveal Melanoma: A Proposed OCT-Based Grading System

N. Horgan; C. L. Shields; A. Mashayekhi; M. A. Materin; P. F. Salazar; M. O'Regan; J. A. Shields

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):48.

Advertisement